A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"

J Thorac Oncol. 2024 Sep;19(9):e44-e45. doi: 10.1016/j.jtho.2024.07.001.
No abstract available

Publication types

  • Letter

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / blood
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Circulating Tumor DNA* / blood
  • Circulating Tumor DNA* / genetics
  • Humans
  • Lung Neoplasms* / blood
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Mutation*
  • Piperazines
  • Proto-Oncogene Proteins p21(ras)* / genetics
  • Pyridines / therapeutic use
  • Pyrimidines

Substances

  • Proto-Oncogene Proteins p21(ras)
  • Circulating Tumor DNA
  • KRAS protein, human
  • sotorasib
  • Pyridines
  • Piperazines
  • Pyrimidines